The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement

A B K Abrahao; S Karim; B Colwell; S Berry; J Biagi

doi:10.3747/co.24.3757

The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement

Curr Oncol. 2017 Dec;24(6):390-400. doi: 10.3747/co.24.3757. Epub 2017 Dec 20.

Authors

A B K Abrahao¹, S Karim², B Colwell³, S Berry¹, J Biagi⁴

Affiliations

¹ Department of Oncology, Sunnybrook Health Sciences Centre, Toronto, ON.
² Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, ON.
³ Division of Medical Oncology, Dalhousie University, Halifax, NS.
⁴ Department of Oncology, Queen's University, Kingston, ON.

Abstract

In recently published data, the predictive value of primary tumour location for the treatment of metastatic colorectal cancer with available biologic therapies has been explored. Recognizing the potential effect of those data on clinical practice, we convened a meeting of Canadian experts who treat metastatic colorectal cancer to develop a set of national, evidence-based treatment guidelines based on primary tumour location. This report summarizes the relevant evidence and presents the consensus recommendations of those experts.

Keywords: Metastatic colorectal cancer; RAS wild-type; consensus statements; egfr monoclonal antibodies; predictive value; primary tumour location; prognostic value; tumour side.